Equillium to Participate in the 38th Annual Roth Conference

Core Viewpoint - Equillium, Inc. is actively engaging with investors at the upcoming 38th Annual Roth Conference for Growth Companies, highlighting its commitment to transparency and investor relations [1]. Company Overview - Equillium is a biotechnology innovator focused on developing novel therapies for severe autoimmune and inflammatory disorders [2]. - The company's lead therapeutic candidate, EQ504, is designed as a potent and selective aryl hydrocarbon receptor modulator with a non-immunosuppressive mechanism of action [2]. - EQ504 has potential applications for targeted local delivery in treating ulcerative colitis and other gastrointestinal diseases, as well as inhaled formulations for inflammatory lung diseases [2].